The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Performance in the first quarter aligned with internal expectations, characterized by the strategic completion of the Exact Sciences acquisition to establish a high-growth beachhead in cancer diagnostics.

Medical Device growth of 8.5% was underpinned by double-digit performance in Electrophysiology, Heart Failure, and Rhythm Management, offsetting a weaker-than-expected respiratory testing season.

Nutrition results reflect a deliberate transition toward volume-driven growth following strategic pricing actions in 2025, with early data indicating that volume recovery is beginning to follow these adjustments.

The Core Lab Diagnostics business is navigating a recovery phase as it laps significant prior-year headwinds in China related to volume-based procurement (VBP) and post-COVID dynamics.

Management attributes the 7.5% growth in Diabetes Care to a temporary international tender renewal delay and a difficult year-over-year comparison involving 2025 shelf-restocking cycles.

Strategic positioning in Electrophysiology was bolstered by the earlier-than-planned launch of two new pulsed field ablation (PFA) catheters, Volt and TactiFlex Duo.

Full-year 2026 comparable sales growth is projected at 6.5% to 7.5%, assuming the full-year inclusion of Exact Sciences in both current and prior periods.

Management anticipates a growth acceleration in the second half of the year, driven by the normalization of Nutrition volumes and the broadening of new product launches in Electrophysiology.

Guidance for the remainder of the year adopts a conservative stance on respiratory testing, choosing not to forecast a compensatory strong season in Q4 following the weak Q1 results.

The Exact Sciences acquisition is expected to contribute approximately $3 billion in incremental sales for 2026, though it introduces a $0.20 dilutive impact to adjusted EPS due to financing costs.

Future growth in Diabetes Care is predicated on upcoming catalysts, including potential CMS coverage expansion for type 2 non-insulin users and the launch of a dual-analyte glucose-ketone sensor.

The acquisition of Exact Sciences closed on March 23, 2026, leading to the adoption of 'comparable sales growth' as the primary metric to provide an apples-to-apples portfolio view.

Financing costs related to the Exact Sciences transaction were absorbed earlier than originally planned, impacting first-quarter adjusted earnings per share.

Structural changes included moving the left atrial appendage (LAA) closure business from Structural Heart to Electrophysiology to better align with physician call points and accelerate adoption.

Management noted that while shipping lanes in the Middle East have become constrained, there has been no material impact on demand or reimbursement, with mitigation strategies focused on localized inventory.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management dismissed concerns over market saturation, citing a total addressable market of 70 million to 80 million people globally compared to the current 10 million to 12 million users.

Growth is expected to be non-linear, driven by specific catalysts such as international reimbursement expansion and the entry into the non-insulin-using type 2 diabetes segment.

The acquisition is viewed as a platform for the entire cancer diagnostics span, including screening, therapy selection, and minimal residual disease (MRD) testing.

Abbott intends to leverage its global distribution and regulatory infrastructure to accelerate Cologuard's international penetration, which is currently very low.

Management expects to grow faster than the EP market by year-end as they transition from limited market release to full commercial launch of their PFA portfolio.

The Volt PFA system is being positioned as a differentiated offering due to its 'conscious sedation' compatibility and preliminary data suggesting more durable lesions compared to first-generation PFA.

Volume recovery is being tracked weekly; management confirmed that where retailers have passed price reductions to consumers, immediate volume elasticity has been observed.

The transition back to a sustainable balance between price and volume is expected to continue improving throughout the fiscal year.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.